
PellePharm, Inc.: A US-based pharmaceutical company specializing in treatments for basal cell conditions.
PellePharm, Inc., founded in Menlo Park, United States, focuses on developing and producing pharmaceutical products aimed at treating basal cell conditions. With a core mission to improve the quality of life for patients suffering from basal cell nevus syndrome and sporadic basal cell carcinomas, PellePharm offers innovative drug solutions tailored to these specific dermatological needs. The company is dedicated to advancing medical research and providing effective treatments that address unmet needs in dermatology.
Notable affiliated individuals include experienced professionals in the pharmaceutical industry, although specific names are not provided. PellePharm has garnered attention from investors interested in cutting-edge dermatological treatments. The company's key achievements include the development of promising drug candidates that have shown efficacy in clinical trials. PellePharm's impact lies in its commitment to enhancing patient care and offering new hope for those affected by challenging skin conditions.

Pelage Pharma
pelagepharma.com

PleoPharma
pleopharma.com

Lipella Pharmaceuticals
lipella.com

SkinJect
skinjectpatch.com

Palkion

Microdermis

Sonoma Pharmaceuticals

Pelican Therapeutics

Thesan Pharmaceuticals
thesanpharma.com

Timber Pharmaceuticals

Pharmatrophix
pharmatrophix.com

DermBiont
dermbiont.com

Surface Pharmaceuticals
surfacepharma.com

Palleon Pharmaceuticals
palleonpharma.com

Soltego
soltego.com
Companies similar to PellePharm include Pelage Pharma, PleoPharma, Lipella Pharmaceuticals and SkinJect.
PellePharm was founded in 2012.
PellePharm's headquarters is located in Menlo Park, CA, US.
PellePharm's most recent funding round was for $7.5M (USD) in June 2018.
As of Jun 28, 2018, PellePharm has raised a total of $38.9M (USD).
PellePharm has 11 employees as of Feb 5, 2024.